NASDAQ:CTSO Cytosorbents (CTSO) Stock Price, News & Analysis $1.00 -0.29 (-22.48%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.98 -0.03 (-2.50%) As of 07/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cytosorbents Stock (NASDAQ:CTSO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cytosorbents alerts:Sign Up Key Stats Today's Range$0.93▼$1.1250-Day Range$0.81▼$1.2952-Week Range$0.71▼$1.61Volume575,953 shsAverage Volume149,373 shsMarket Capitalization$62.61 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey. Read More Cytosorbents Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreCTSO MarketRank™: Cytosorbents scored higher than 36% of companies evaluated by MarketBeat, and ranked 769th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCytosorbents has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCytosorbents has only been the subject of 2 research reports in the past 90 days.Read more about Cytosorbents' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cytosorbents are expected to grow in the coming year, from ($0.30) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytosorbents is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytosorbents is -3.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCytosorbents has a P/B Ratio of 5.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cytosorbents' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.46% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently decreased by 2.05%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCytosorbents does not currently pay a dividend.Dividend GrowthCytosorbents does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.46% of the float of Cytosorbents has been sold short.Short Interest Ratio / Days to CoverCytosorbents has a short interest ratio ("days to cover") of 13.6, which indicates bearish sentiment.Change versus previous monthShort interest in Cytosorbents has recently decreased by 2.05%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.37 News SentimentCytosorbents has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Cytosorbents this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for CTSO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cytosorbents insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.30% of the stock of Cytosorbents is held by insiders.Percentage Held by InstitutionsOnly 32.87% of the stock of Cytosorbents is held by institutions.Read more about Cytosorbents' insider trading history. Receive CTSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter. Email Address CTSO Stock News HeadlinesCytosorbents stock plunges after regulatory setbacks for key deviceJuly 2 at 6:18 PM | investing.comCytoSorbents to Appeal Canadian Rejection of License Application for DrugSorb-ATRJuly 2 at 8:16 AM | marketwatch.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history. | Paradigm Press (Ad)CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATRJuly 2 at 7:00 AM | prnewswire.comD. Boral Capital Reiterates "Buy" Rating for Cytosorbents (NASDAQ:CTSO)June 27, 2025 | americanbankingnews.com7CTSO : Deep Dive Into CytoSorbents Stock: Analyst...June 25, 2025 | benzinga.comCytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATRJune 24, 2025 | finanznachrichten.deCytoSorbents Q1 2025 slides: Revenue dips 3% as company targets breakeven by year-end - Investing.comJune 24, 2025 | investing.comSee More Headlines CTSO Stock Analysis - Frequently Asked Questions How have CTSO shares performed this year? Cytosorbents' stock was trading at $0.91 at the beginning of 2025. Since then, CTSO stock has increased by 9.9% and is now trading at $1.00. View the best growth stocks for 2025 here. How were Cytosorbents' earnings last quarter? Cytosorbents Corporation (NASDAQ:CTSO) announced its quarterly earnings results on Wednesday, May, 14th. The medical research company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The medical research company earned $8.73 million during the quarter, compared to analyst estimates of $9.01 million. Cytosorbents had a negative net margin of 41.77% and a negative trailing twelve-month return on equity of 105.04%. Read the conference call transcript. How do I buy shares of Cytosorbents? Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cytosorbents own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cytosorbents investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Corning (GLW), UnitedHealth Group (UNH) and Docusign (DOCU). Company Calendar Last Earnings5/14/2025Today7/02/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:CTSO CIK1175151 Webwww.cytosorbents.com Phone(732) 329-8885Fax732-329-8650Employees220Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$10.00 Low Stock Price Target$1.00 Potential Upside/Downside+450.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.72 million Net Margins-41.77% Pretax Margin-47.90% Return on Equity-105.04% Return on Assets-29.18% Debt Debt-to-Equity Ratio0.98 Current Ratio2.61 Quick Ratio2.30 Sales & Book Value Annual Sales$35.60 million Price / Sales1.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book5.00Miscellaneous Outstanding Shares62,610,000Free Float58,039,000Market Cap$62.61 million OptionableOptionable Beta1.19 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CTSO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredMake 22x more from this summer’s Bitcoin boomBitcoin is on fire again. Wall Street’s piling in. ETFs are smashing volume records. And regular investors ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytosorbents Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytosorbents With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTSO Stock Alerts